Philochem
innovating chemistry

PRESS RELEASE

Philochem AG (a company of the Philogen group) announces Board of Appeal decision on Philochem's Patent on Production of Encoded Chemical Libraries

Zürich, Switzerland, February 19, 2023 – Philochem AG, a wholly owned subsidiary of Philogen S.p.A., focused on the discovery and development of small molecule pharmaceuticals for the imaging and therapy of cancer and other serious conditions, announces that the Board of Appeal at the European Patent Office has confirmed the decision of the Opposition Division at the European Patent Office, rejecting the notice of opposition against Philochem's European Patent 3083957 filed by NuEvolution A/S.

The decision dismissed all opposition grounds filed by NuEvolution and all claims of the patent were maintained.

The European Patent 3083957 entitled "Production of Encoded Chemical Libraries", granted on May 23rd, 2018, relates to important features of proprietary DNA-encoded chemical libraries ("ESAC 2+1" technology). The patent is directed to inventions that are instrumental for the isolation and discovery of novel ligands for biologically relevant targets.

"We are pleased that the Board of Appeal at the European Patent Office has reconfirmed the full validity of this important patent" **said Prof. Dario Neri, CEO of the Philogen Group and Member of the Philochem Board**, "As a science-driven company, we strongly encourage everyone in the field to collaborate rather than to litigate patents. Philochem is committed to advancing technologies for the benefit of patients and welcomes every opportunity to join forces in the pursuit of breakthrough pharmaceuticals."

About Philochem and the Philogen Group
Philochem is a fully owned subsidiary of the Philogen Group, a Swiss-Italian, clinical-stage biotechnology company listed on the Italian Stock Exchange. Philogen is engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen's strategy is to selectively deliver bioactive agents (such as radionuclides, cytokines or drugs) to the site of disease using antibodies or small organic ligands. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem near Zurich, Switzerland. Philogen has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com and www.philochem.com.

Contacts:

For Philogen
Dr. Emanuele Puca
Investor Relations
+41 (0) 43 544 88 00
emanuele.puca@philogen.com